Does Dr. LANA MELENDRES-GROVES have financial conflicts of interest?

Dr. LANA MELENDRES-GROVES (MD) has received a total of $812,515 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $812,515 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LANA MELENDRES-GROVES?

According to CMS Open Payments data, Dr. LANA MELENDRES-GROVES received funding from UNITED THERAPEUTICS CORPORATION ($417,584), ACTELION PHARMACEUTICALS US ($191,684), and MERCK SHARP & DOHME ($128,116).

Does Dr. LANA MELENDRES-GROVES receive research grants or speaking fees?

Dr. LANA MELENDRES-GROVES has received $812,515 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LANA MELENDRES-GROVES

MDReal-Time Hydrated

Specialty: Internal Medicine, Pulmonary Disease

Practice Location: ALBUQUERQUE, NM 87131

NPI Number: 1548309537

LIFETIME INDUSTRY VALUE

$812,515

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. MELENDRES-GROVES is a verified Internal Medicine, Pulmonary Disease practitioner based in ALBUQUERQUE, NM.

Between 2021 and 2025, Dr. MELENDRES-GROVES had an overall industry promotional and research financial footprint of $812,515 as recorded in the federal CMS Open Payments database.

$812,515 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. MELENDRES-GROVES's primary funding source is UNITED THERAPEUTICS CORPORATION, which accounts for $417,584 (representing 51.4% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

UNITED THERAPEUTICS CORPORATION

Rank 1

$417,584

51.4%

ACTELION PHARMACEUTICALS US

Rank 2

$191,684

23.6%

MERCK SHARP & DOHME

Rank 3

$128,116

15.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.